Selective Protection of Normal Cells from Chemotherapy, While Killing Drug-Resistant Cancer Cells

Oncotarget published this review on March 11, 2023 in Volume 14, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells" by Dr. Mikhail V. Blagosklonny from Roswell Park Comprehensive Cancer Center, Buffalo, NY.
#openaccess #cancer #research #cancertherapy #chemotherapy #braintumorresearch #openscience #peerreview #journal #publication #review #oncology #cancertreatment #cancerpatients #meded

DOI - https://doi.org/10.18632/oncotarget.2...

Correspondence to - Mikhail V. Blagosklonny - [email protected], [email protected]

Abstract

Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. Paradoxically, cancer resistance to certain therapies can be exploited for protection of normal cells, simultaneously enabling the selective killing of resistant cancer cells by using antagonistic drug combinations, which include cytotoxic and protective drugs. Depending on the mechanisms of drug-resistance in cancer cells, the protection of normal cells can be achieved with inhibitors of CDK4/6, caspases, Mdm2, mTOR, and mitogenic kinases. When normal cells are protected, the selectivity and potency of multi-drug combinations can be further enhanced by adding synergistic drugs, in theory, eliminating the deadliest cancer clones with minimal side effects. I also discuss how the recent success of Trilaciclib may foster similar approaches into clinical practice, how to mitigate systemic side effects of chemotherapy in patients with brain tumors and how to ensure that protective drugs would only protect normal cells (not cancer cells) in a particular patient.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/deta...

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - oncology, resistance, cyclotherapy, trilaciclib, rapamycin

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud -   / oncotarget  
Facebook -   / oncotarget  
Twitter -   / oncotarget  
Instagram -   / oncotargetjrnl  
YouTube -    / @oncotargetjournal  
LinkedIn -   / oncotarget  
Pinterest -   / oncotarget  
Reddit -   / oncotarget  

Media Contact
[email protected]
18009220957